Related references
Note: Only part of the references are listed.Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms
K. Kubo et al.
PHARMACOGENOMICS JOURNAL (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry
Harsh Golwala et al.
AMERICAN HEART JOURNAL (2016)
Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study)
Celina Yong et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese
Wu-Tao Zeng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Verification of five pharmacogenomics-based warfarin administration models
Meiqin Lin et al.
INDIAN JOURNAL OF PHARMACOLOGY (2016)
Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans
Sameh Alzubiedi et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Genomics is failing on diversity
Alice B. Popejoy et al.
NATURE (2016)
A systematic analysis and comparison of warfarin initiation strategies
Benjamin French et al.
PHARMACOGENETICS AND GENOMICS (2016)
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients
Sun-Mi Cho et al.
YONSEI MEDICAL JOURNAL (2016)
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature
Elizabeth J. J. Berm et al.
PLOS ONE (2016)
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics
Jorge Duconge et al.
PLOS ONE (2016)
Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients
Nian-Xin Jiang et al.
BIOMEDICAL REPORTS (2016)
Warfarin pharmacogenomics and African ancestry
Elvin T. Price
BLOOD (2015)
Race influences warfarin dose changes associated with genetic factors
Nita A. Limdi et al.
BLOOD (2015)
Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin
Khagendra Dahal et al.
CHEST (2015)
Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX
Alison E. Fohner et al.
PHARMACOGENETICS AND GENOMICS (2015)
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans
Katarzyna Drozda et al.
PHARMACOGENETICS AND GENOMICS (2015)
Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis
Joyce H. S. You
PHARMACOGENOMICS (2015)
Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration
Paulo Caleb Junior Lima Santos et al.
PHARMACOGENOMICS (2015)
Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database
Rong Liu et al.
PLOS ONE (2015)
Warfarin pharmacogenetics
Julie A. Johnson et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2015)
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon
Talitha I. Verhoef et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
J. Pink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Warfarin Pharmacogenetics: An Illustration of the Importance of Studies in Minority Populations
M. A. Perera et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population
Dhakchinamoorthi Krishna Kumar et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Dosage Individualization of Warfarin Using Artificial Neural Networks
Mohammad I. Saleh et al.
MOLECULAR DIAGNOSIS & THERAPY (2014)
Verification of Pharmacogenetics-Based Warfarin Dosing Algorithms in Han-Chinese Patients Undertaking Mechanic Heart Valve Replacement
Li Zhao et al.
PLOS ONE (2014)
A Pharmacogenetics-Based Warfarin Maintenance Dosing Algorithm from Northern Chinese Patients
Jinxing Chen et al.
PLOS ONE (2014)
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans
W. Hernandez et al.
PHARMACOGENOMICS JOURNAL (2014)
Using systems approaches to address challenges for clinical implementation of pharmacogenomics
Jason H. Karnes et al.
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2014)
Pharmacogenomics of warfarin in populations of African descent
Guilherme Suarez-Kurtz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
Minoli A. Perera et al.
LANCET (2013)
A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon
Talitha I. Verhoef et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Munir Pirmohamed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients
Xiaoying Lei et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Anne Holbrook et al.
CHEST (2012)
Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients
Ruijuan Liang et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Association of the GGCX (CAA) 16/17 repeat polymorphism with higher warfarin dose requirements in African Americans
Larisa H. Cavallari et al.
PHARMACOGENETICS AND GENOMICS (2012)
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans
Adam Bress et al.
PHARMACOGENOMICS (2012)
Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients
Alga S. Ramos et al.
PHARMACOGENOMICS (2012)
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record
Andrea H. Ramirez et al.
PHARMACOGENOMICS (2012)
The future of warfarin pharmacogenetics in under-represented minority groups
Larisa H. Cavallari et al.
FUTURE CARDIOLOGY (2012)
Pharmacogenomics of Warfarin dose requirements in Hispanics
Larisa H. Cavallari et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry
Mariana Rodrigues Botton et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans
M. A. Perera et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Development and Comparison of a Warfarin-Dosing Algorithm for Korean Patients With Atrial Fibrillation
Hyun-Jung Cho et al.
CLINICAL THERAPEUTICS (2011)
Pharmacoeconomic evaluation of warfarin pharmacogenomics
Joyce H. S. You
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Emergency Hospitalizations for Adverse Drug Events in Older Americans
Daniel S. Budnitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Nita A. Limdi et al.
BLOOD (2010)
A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans
D. Voora et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese
Pei-Chieng Cha et al.
HUMAN MOLECULAR GENETICS (2010)
A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
Lisa M. Meckley et al.
PHARMACOECONOMICS (2010)
Gamma-glutamyl carboxylase and its influence on warfarin dose
Cristi R. King et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
Mark H. Eckman et al.
ANNALS OF INTERNAL MEDICINE (2009)
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
Virginia Perez-Andreu et al.
BLOOD (2009)
Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation
Amanda R. Patrick et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2009)
Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Judith A. Aberg et al.
CLINICAL INFECTIOUS DISEASES (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
Rianne M. F. van Schie et al.
PHARMACOGENOMICS (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Stuart J. Connolly et al.
CIRCULATION (2008)
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
B. F. Gage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients
J. A. Perini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Warfarin pharmacogenetics
Nita A. Limdi et al.
PHARMACOTHERAPY (2008)
Factors influencing warfarin dose requirements in African-Americans
Kathryn M. Momary et al.
PHARMACOGENOMICS (2007)
Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation
Albert Yuh-Jer Shen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
Elaine M. Hylek et al.
CIRCULATION (2007)
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control - Results from SPORTIF III and IV
Harvey D. White et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Pharmacogenetics of warfarin: current status and future challenges
M. Wadelius et al.
PHARMACOGENOMICS JOURNAL (2007)
Association of warfarin dose with genes involved in its action and metabolism
Mia Wadelius et al.
HUMAN GENETICS (2007)
The influence of ethnicity on warfarin dosage requirement
MTN Dang et al.
ANNALS OF PHARMACOTHERAPY (2005)
Interindividual variability in sensitivity to warfarin - Nature or nurture?
R Loebstein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
